Effect of polymorphisms in interleukin-18 gene on the susceptibility to coronary artery disease in a Chinese population

Abstract

ABSTRACT. Coronary artery disease (CAD) has a high mortality rate in several countries. Interleukin (IL)-18 has been previously correlated with atherosclerotic plaque rupture. In this case-control study, the relationship between -607A/C and -372C/G promoter polymorphisms in IL-18 and risk of CAD development was investigated. A total of 326 CAD patients were consecutively recruited from the First Hospital of Yulin between March 2013 and May 2015. The IL-18 -607A/C and -372C/G polymorphisms were genotyped by polymerase chain reactionrestriction fragment length polymorphism. Patients with CAD had a higher body mass index, a history of hypertension or diabetes (all P < 0.001), cigarette smoking habit (P = 0.002); as well as higher plasma total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels (all P < 0.001) and lower high-density lipoprotein cholesterol (P < 0.001) levels compared to the control subjects. Unconditional logistic regression analysis revealed significant correlation between the CC genotype of IL-18 -607A/C and CAD development, compared to the AA genotype [adjusted odds ratio (OR) = 2.42; 95% confidence interval (CI) = 1.52-3.89; P < 0.001]. The recessive model showed a significant association between the CC genotype of IL-18 -607A/C and an increased risk of CAD, compared to the AA+AC genotype (OR = 2.51, 95%CI = 1.65-3.85). However, IL-18 -372C/G did not contribute to the risk of glioma development in the co-dominant, dominant, and recessive models. Therefore, the IL-18 -607C/A polymorphism was significantly correlated with the risk of CAD development.

Association between polymorphisms in interleukin-18 promoter and risk of coronary artery disease: a meta-analysis

“…They reported no significant association between genotypes and alleles and CAD. However, contrary conclusions were reported by other studies [17,10,26,27]. In our meta-analysis, we observed a significant association between the -607 polymorphism (rs1946518) and CAD, in which the -607 polymorphism (rs1946518) was negatively correlated with CAD.…”

Leptin and Associated Mediators of Immunometabolic Signaling: Novel Molecular Outcome Measures for Neurostimulation to Treat Chronic Pain

“…Hence, understanding mechanisms of relevant comorbidities underlying chronic pain (e.g., metabolism, depression, and anxiety) may help to develop novel diagnostic and treatment options. In addition to their role in the transition and maintenance of chronic pain, most of the described mediators have been associated with a broad range of chronic disorders (neurological, psychiatric, cardiovascular, and metabolic) due to their multifunctional characteristics, which in turn may explain the clinically observed co-occurrence of the so-called comorbidities [9,10,11,12]. Spinal and peripheral neurostimulation therapies have repeatedly shown meaningful pain relief in recent studies to treat various chronic pain disorders (failed back surgery, complex regional pain syndrome (CRPS), and migraine) targeting the spinal cord, the dorsal root ganglia (DRG), and peripheral nerves (vagus nerve stimulation; VNS) [3,4,5,6,7,8].…”